Is It Too Late to Buy Eli Lilly Stock?
Shares of Eli Lilly (NYSE: LLY) have climbed an incredible 44% since the end of February. Optimism for its weight-management franchise is heating up, but maybe it's a little too hot already.
Is this pharmaceutical industry giant still a good stock to buy? Let's measure its strengths against its weaknesses to find out.
Last May, Mounjaro earned its first approval, and it's already on pace to deliver $3 billion in revenue this year. That's all the more impressive when you consider that it's only approved to treat patients with type 2 diabetes.
Source Fool.com
